ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial
October 22, 2020 07:30 ET
|
ASLAN PHARMACEUTICALS LIMITED
-- ASLAN has initiated recruitment of patients into third dose cohort at sites in the US, Australia and Singapore following successful safety review of second cohort -- ASLAN004 found to be...
ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions
October 16, 2020 05:25 ET
|
ASLAN PHARMACEUTICALS LIMITED
-- ASLAN believes ASLAN003 has the potential to be the most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH...
ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study
September 21, 2020 06:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to...
ASLAN Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 10, 2020 03:08 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to...
ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 Study
August 24, 2020 03:27 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Aug. 24, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Appoints Kenneth Kobayashi, MD, as Chief Medical Officer
August 03, 2020 03:17 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Aug. 03, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Announces the Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange
July 17, 2020 06:08 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, July 17, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
July 13, 2020 08:06 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 11, 2020 05:34 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, May 11, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...
UPDATE - ASLAN Pharmaceuticals Temporarily Pauses Recruitment of New Patients Into ASLAN004 Study Due to COVID-19
April 13, 2020 05:17 ET
|
ASLAN PHARMACEUTICALS LIMITED
ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitment Study remains on track to report interim,...